Pasithea's PAS-004 shows prolonged stable disease in four Phase 1 cancer trial patients
KTTA•KTTA•KTTA•KTTA•In a 37-patient Phase 1 trial, four heavily pretreated patients had prolonged stable disease, including two with melanoma that progressed on prior targeted therapy. Pasithea reported mild or moderate treatment-related side effects, no dose-limiting toxicities and no serious treatment-related adverse events or treatment discontinuations.
Pasithea Therapeutics is presenting results from its ongoing Phase 1 PAS-004 cancer trial at ESMO Congress 2026 in Madrid. The 37-patient study showed prolonged stable disease in four heavily pretreated patients, including two with melanoma that progressed on prior targeted therapy.
Treatment-related side effects were mild or moderate, with no treatment discontinuations or serious treatment-related adverse events reported. No dose-limiting toxicities occurred, and the drug’s pharmacokinetic profile supported long-term, once-daily dosing.
